Jacobs Levy Equity Management
FLGT icon

Jacobs Levy Equity Management’s Fulgent Genetics FLGT Stock Holding History

Jacobs Levy Equity Management’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16M Buy
782,116
+425,757
+119% +$7.22M 0.06% 254
2026
Q1 		$5.67M Buy
+356,359
New +$7.73M 0.02% 394

Other funds holding FLGT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Jacobs Levy Equity Management's FLGT Position: Q2 2026 in Review

Jacobs Levy Equity Management increased its Fulgent Genetics (FLGT) stake by 119% in Q2 2026, buying an estimated $7.22M and bringing the position to 782,116 shares worth $16M. The position accounts for 0.06% of the portfolio, ranked #254.

Jacobs Levy Equity Management first reported a position in FLGT in Q1 2026 and has held it in 2 quarters since. 142 funds tracked by Wall St. Rank hold FLGT as of Q2 2026.

  • Jacobs Levy Equity Management held 782,116 shares of Fulgent Genetics worth $16M as of Q2 2026.
  • Jacobs Levy Equity Management bought 425,757 Fulgent Genetics shares in Q2 2026, an estimated $7.22M.
  • Fulgent Genetics made up 0.06% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #254 holding.
  • Jacobs Levy Equity Management first reported a position in Fulgent Genetics in Q1 2026 and has held it in 2 quarters since.
  • 142 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.